Table 1.

Literature Review of the Use of ECT in COVID-19 NPS

Authors & year	Patient age and sex	Psychiatric comorbidities	Indication for ECT	Pharmacological treatment	Method of C-19 diagnosis	Notable laboratorty results	# Treatments	Treatment outcome
Kashaninasab et al., 202017	25-year-old male	None reported	Mania, severe, with psychotic features	Initially haloperidol 20 mg IM daily, biperiden 10 mg IM daily, and chlorpromazine 100 mg IM daily; gradually replaced by 1500 mg sodium valproate daily	Clinical; CT Chest		6	Patient was discharged in stable condition
Chacko et al., 202018	52-year-old male	None	Psychosis, suicidality	Fluoxetine 20 mg daily, olanzapine 5 mg po BID, and lorazepam up to 2 mg po BID	Clinical; SARS-CoV-2 IgG (+), 3 weeks after discharge	Elevated LFTs and inflammatory markers (ESR = 40 mm/hr, CRP = 1.5 mg/dL, D-dimer = 1003 ng/mL)	6	Patient was discharged in improved condition with no thoughts of suicide
Deocleciano de Araujo et al., 202119	50-year-old male	Mild IDD, well-controlled epilepsy	Catatonia	Diazepam 10 mg IV QID, later substituted by lorazepam 2 mg po TID; sertraline 25 mg daily, and olanzapine 5 mg daily	PCR	CSF protein (55 mg/dL), CK 8819 U/l, WBC 20.8 x 109/L	10	Patient was discharged “fully recovered” and “back to his usual self”

CRP = C-reactive protein; CSF = cerebrospinal fluid; ECT = electroconvulsive therapy; ESR = erythrocyte sedimentation rate; IDD = intellectual and developmental disabilities; PCR = polymerase chain reaction; SARS-CoV-2 = Severe Acute Respiratory Syndrome Coronavirus 2.